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Conclusions: BLEEDRS – an adapted simplification of HASBLED score predicts major
bleeding events after PCI.
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Background: Oxidation of lipoproteins generates multiple bioactive oxidized lipids that
affect atherothrombosis and endothelial dysfunction, but direct evidence of their role
during therapeutic procedures is lacking. Liberated oxidized lipids may result in no-reflow
phenomenon, myocardial infarction and stroke. To assess whether oxidized vasoactive
lipids are released downstream from atherosclerotic plaques following percutaneous
coronary and peripheral interventions we undertook a lipidomic analysis of material
recovered from distal embolic protection devices from different vascular beds.
Methods: The presence of specific oxidized lipids was assessed in embolized material
captured by distal embolic protection devices during saphenous vein graft, carotid, renal,
and superficial femoral artery interventions. Following lipid extraction, specific oxidized
phospholipids (OxPL) and cholesterol esters (OxCE) were quantified in 12 filters using
liquid chromatography, tandem mass spectrometry.
Results: Phosphatidylcholine (PC) containing OxPL, including 1-palmitoyl-2-(5-
oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC), C9 aldehyde PC, E2 and F2 iso-
prostane PC, and hydroperoxy PC were identified in the extracted lipid portion. The major
oxidized PC by mass was the C9 aldehyde PC, representing 38% of all oxidized PL.
Several species of OxCE, such as aldehyde, hydroperoxide, oxide and epoxy cholesterol
ester derivatives from cholesteryl linoleate and cholesteryl arachidonate, were also
present. The pattern of OxPL and OxCE within filters correlated well with molecules
found in various forms of oxidized LDL and did not differ significantly in different
vascular beds. The presence of OxPL was also confirmed using ELISA and immunohis-
tochemistry.
Conclusions: This is the first documentation of the presence and direct release of
oxidized lipids from atherosclerotic plaques during percutaneous interventions from
multiple vascular beds in humans. The release of such oxidized lipids into the microcir-
culation may mediate some of the adverse clinical outcomes that result during these
intravascular interventions.
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Background: An intra-coronary device becoming stuck is a very uncommon compli-
cation that may lead to tragic consequences such as occlusion of the artery and systemic
embolism.
Methods: Of 14,198 lesions in 13,188 patients who underwent PCI between 1999 and
2011, 40 device stuck (0.28%) incidents occurred during PCI procedures. The incidence,
outcomes and management of these device stuck occurrences were evaluated.
Results: The overall procedural success rate was 97.8% (13,884/14,198). The stuck
devices included stents (n20; 50%), wires (n14; 35%), balloons (n4; 10%),
intra-vascular ultrasound (n1; 2.5%), and rotablator burrs (n1; 2.5%), respectively.
Management of the complication and acute/long-term outcomes are shown in the table. Of
54 instances of device stuck, 15 (37.5%) were retrieved successfully, and 7 (18%)
resulted in rupture and were left in the coronary artery. Thirty-seven patients recovered in
the cath-lab and the rest (N3) were referred to emergency CABG. At 1-year follow-up,
all patients were alive, although the segment of the coronary artery where the device
stuck occurred was occluded in 2 cases on agiographic findings.
Conclusions: Although the rate of this complication during PCI was very low, all cases
were solved with optimal treatment and all patients survived at 1-year follow-up. A safe
procedure with careful device manipulation should be required for PCI, with appropriate
management leading to better outcomes.
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Background: Recent advances in antithrombotic therapy for STEMI are accompanied
by an increased risk of bleeding. So far, the CRUSADE score for bleeding risk has only
been validated in NSTEMI.
Methods: The risk of in-hospital major CRUSADE bleeding and 1-year mortality after
primary PCI for STEMI was studied in consecutive patients who received upfront
abciximab, periprocedural heparin and loading doses of aspirin and clopidogrel.
Results: In total, 965 STEMI patients (6112 yrs, 76% men) were stratified according
to the CRUSADE bleeding risk score (Table). Median CRUSADE score was 21 (14-29).
Bleeding was common (21%) ranging from 11% in the very low risk group up to 69% in
the very high risk group. Most common bleeding site was the femoral access site. In 3
patients, bleeding most likely led to death. Survival analysis demonstrated 1-year
mortality rates of 9.2% in bleeders vs. 2.5% in non-bleeders (p0.001, Figure).
Assessment of the CRUSADE risk score by ROC curve resulted in an area under the
curve of only 0.68 (0.64-0.73, p0.001).
CRUSADE bleeding risk score Non-bleeders Bleeders
Very low risk 399 (88.9%) 50 (11.1%)
Low risk 230 (75.9%) 73 (24.1%)
Moderate risk 95 (69.3%) 42 (30.7%)
High risk 39 (65.0%) 21 (35.0%)
Very high risk 5 (31.3%) 11 (68.8%)
In-hospital major bleeding in CRUSADE bleeding risk score categories
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Conclusions: Major bleeding is common after primary PCI for STEMI and associated
with increased mortality during 1 year follow-up. The CRUSADE bleeding risk score
underestimated the risk of major bleeding and therefore the use of this tool might be
limited in STEMI.
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Background: Red cell distribution width (RDW), a numerical measure of the variability
of the size of circulating erythrocytes, has been shown to be an independent predictor of
mortality in cardiovascular disease, and in patients undergoing PCI. The purpose of this
study was to determine if RDW is a prognostic marker of major post-PCI bleeding.
Methods: The study population included 4387 patients with coronary artery disease who
were subjected to PCI. The RDW was derived from a complete blood count (CBC) drawn
before PCI. Major bleeding was defined as hematocrit decrease15%, transfusion of2
units of packed red blood cells, gastrointestinal or intracerebral bleeding. Multivariable
logistic analysis of major in-hospital bleeding was performed using a logistic regression
model. Baseline characteristics associated with bleeding were included in the model.
Results: In 250 patients with a bleed, RDW was significantly higher than in the 4137
patients who did not bleed (14.4 	/ 2.1% vs 13.5 	/ 1.6%, p 0.001). On
multivariable analysis, after adjustment for known correlates of bleeding, RDW was a
significant predictor of bleeding (OR 1.14, 95% CI 1.05-1.23, p0.002). (Table 1)
Conclusions: RDW, an easily obtainable marker, has a strong independent linear
relationship with major post-procedure bleeding in patients undergoing PCI. These data
suggest that further investigation is necessary to determine the relationship of RDW and
bleeding post-PCI.
Independent Correlates of Major Bleeding Post PCI
Variable OR 95% CI p value
RDW 1.14 1.05–1.23 0.002
Male 0.47 0.34–0.64 0.001
BMI 0.97 0.94–1.0 0.021
IABP use 3.42 2.05–5.71 0.001
Cardiogenic Shock 2.28 1.2–4.34 0.012
Acute MI 2.19 1.42–3.38 0.001
Angiomax®(Bivalrudin) 0.53 0.37–0.77 0.001
Closure Device 0.66 0.48–0.90 0.01
TCT-559
On-Treatment Platelet Reactivity Testing Before Coronary Artery Bypass
Surgery. Does It Predict In-Hospital Major Bleeding?
Gabriel Sardi1, Kenneth Kent2, Hironori Kitabata3, Joshua Loh3,
Augusto Pichard4, Lowell Satler5, William Suddath6, Rebecca Torguson7,
Ron Waksman8
1Washington Hospital Center, Washington Dc, DC, 2Washington Hospital center,
Washington, DC, 3Medstar Washington Hospital Center, Washington, DC,
4washsington hospital center, Washington, USA, 5Washington hospital center,
washington, DC, 6Washington Hospital Center, Washington, DC, 7Washington
Hospital center, washington, DC, 8Georgtown University, Washington, DC
Background: Consensus guidelines recommend discontinuation of thienopyridine ther-
apy 5-7 days before planned coronary artery bypass graft (CABG) surgery to reduce
bleeding-related events. However, surgery is often performed within this time period to
reduce the risk of ischemic events. Evidence supporting the use of on-treatment platelet
reactivity testing before CABG is limited.
Methods: Patients undergoing CABG within 5 days of thienopyridine discontinuation
were prospectively enrolled from 08/2010 to 02/2012. On-treatment platelet reactivity
was measured with Verify Now (VN) P2Y12 assay, vasodilator stimulated phosphopro-
tein phosphorylation (VASP) and light transmittance aggregometry (LTA) with 5 and 20
M of ADP. The primary end point was in-hospital major bleeding (IHMB), defined as
bleeding intracranially, that associated with hemodynamic compromise, a hemoglobin
drop of 5 g/dl, or a hematocrit drop of 15%. The relation between platelet reactivity
value and IHMB was assessed with Wilcoxon rank-sum test; its relation with hematocrit
(Htc) drop was evaluated with Spearman correlation.
Results: The population consisted of 80 patients. IHMB occurred in 37 patients (46.3%).
VASP and LTA with 5 M or 20 M of ADP were associated with the primary endpoint
(IHMB). (Table) VN and VASP levels demonstrated an inverse correlation with the
degree of Htc drop after CABG (p0.002 and 0.041, respectively). A VASP platelet
reactivity index (PRI) of 50% is predictive of IHMB (p0.013), but a cut-off value of 230
P2Y12 reaction units (PRU) for VN is not (p0.26). Surgical related bleeding is not
predicted by platelet reactivity testing.
Major bleeding
present (Median [IQ
range])
Major bleeding
absent (Median [IQ
range]) p Value
Verify Now
(PRU)
198 [156–271] 221.5 [195–275] 0.093
VASP (PRI ) 55.2 [25–64] 62.5 [52.5–74.9] 0.004
LTA ADP 5M 39 [31.5–49] 49 [43–56] 0.002
LTA ADP 20M 48.5 [43–65.5] 65 [55–72] 0.002
Conclusions: On-treatment platelet reactivity testing with VASP or LTA 5 M or 20
M of ADP before CABG are able to predict the occurrence IHMB. A VASP PRI value
of 50% may indicate the need to postpone surgery for patients undergoing CABG
within 5 days of thienopyridine discontinuation.
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Background: Coronary no reflow is infrequent complications during percutanous
coronary intervention (PCI), however its impact on long term clinical outcome is not well
studied.
Methods: A total 1926 all comer patients (pts) including acute myocardial infarction
(MI) pts who underwent PCI with DESs were enrolled for this study. Study population
was divided into two groups; no reflow group (n50 pts) and non no reflow group
(n1876 pts). Angiographic at 6 months and clinical outcomes up to 24 months were
compared between the two groups.
Results: Baseline characteristics were similar between the two groups. The incidence of
angiographic no-reflow was in 2.6% (50/1926). At 6 months, no-reflow group had more
incidences of higher late loss. At 24 months clinical follow up, the no-reflow group had
worse clinical outcomes including higher cumulative incidence of total death, Q-MI and
major adverse cardiac events (MACEs, Table).
Conclusions: In the current study, despite of low incidence of no-reflow in general PCI
population, those patients had worse angiographic and clinical outcomes up to 24 months.
Special care should be exercised in this particular subset of pts during and after the
procedure.
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